No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 13 of the 39 quarters in the window, leaving 26 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 10.7x · 10Y median 11.3x · 46th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:43:36.438Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for UroGen Pharma Ltd. (URGN) stock was $41.43 as of Oct 6, 2026, 4:00 PM EDT, down 3.16% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +144.8% · 3-year avg +46.7%/yr · 5-year avg +20.3%/yr
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Biotechnology · Princeton, NJ
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
0.10
Revenue Est.
$90.58M
Last Quarter Results
EPS
$-0.28
vs Estimate
$-0.27
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1URGN | $2.02B | $41.43 | -3.16% | +144.81% | +20.32% | N/A | N/A |
| 2AUPH | $2.02B | $15.69 | -0.19% | +38.29% | -5.88% | +14.53% | vs URGN |
| 3BCRX | $2.02B | $7.95 | -1.85% | +13.22% | -10.02% | +5.82% | vs URGN |
| 4PGNY | $2.03B | $25.91 | +0.19% | +25.46% | -14.83% | N/A | vs URGN |
| 5VCEL | $2.05B | $40.05 | -2.48% | +26.46% | -4.18% | +30.18% | vs URGN |
| 6FTRE | $1.98B | $20.78 | -1.56% | +116.80% | N/A | N/A | vs URGN |
forward FY estimate
N/A
$72.46M
vs Estimate
$63.55M
Consensus Rating
Based on 8 analysts
Average Price Target
$60.00
+44.8% upside
Low
$48.00
Current
$41.43
High
$75.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.02 | $0.10 | $0.36 | 5 |
| Quarter ending Dec 2026 | $-3.60 | $0.40 | $3.13 | 5 |
| Quarter ending Mar 2027 | $0.27 | $0.31 | $0.34 | 3 |
| Quarter ending Jun 2027 | $0.36 | $0.42 | $0.46 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.93 | $-0.22 | $0.22 | 6 |
| FY 2027 | $0.76 | $2.51 | $4.78 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $85.96M | $90.58M | $95.55M | 5 |
| Quarter ending Dec 2026 | $98.63M | $108.22M | $115.84M | 5 |
| Quarter ending Mar 2027 | $102.46M | $114.88M | $124.37M | 4 |
| Quarter ending Jun 2027 | $112.91M | $126.59M | $137.04M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $308.22M | $322.21M | $334.61M | 6 |
| FY 2027 | $478.98M | $541.48M | $640.39M | 6 |
